CTOs on the Move

Pulse Biomedical Inc

www.qrscard.com

 
Pulse Biomedical Inc is a Norristown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.qrscard.com
  • 1305 Catfish Ln Ste 4
    Norristown, PA USA 19403
  • Phone: 610.666.5510

Executives

Name Title Contact Details

Similar Companies

Affiliated Physicians

Affiliated Physicians is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fonix Speech

Fonix Speech, Inc. is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cordant Health Solutions

Based in Denver, Cordant Health Solutions™ provides innovative tools for monitoring and managing behavioral health, chronic pain and criminal justice cases. Our unique programs include pharmacy, clinical laboratory and analytic tools that provide actionable information to protect prescribers, improve outcomes and contain costs. As a leader in rigorous quality and compliance standards, Cordant is committed to developing groundbreaking solutions for payers, clinicians and organizations involved in the substance use disorder, criminal justice and pain management markets. Cordant offers unique risk assessment, monitoring and management tools through its integrated network of laboratories and high-touch pharmacies specializing in the management and dispensing of controlled substances and behavioral health medications. Cordant`s testing protocols and digital case-management tools help clients become more efficient and effective in assessing and managing risk, monitoring patient adherence and improving patient outcomes.

emeds.pk

emeds Pharmacy is an online medical store in Pakistan that aims to provide the best healthcare solutions in the least possible time at your doorstep.

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.